Efficacy and safety of milrinone versus sildenafil in the management of moderate to severe peristent pulmonary hypertention in neonates /
دراسة مدى كفاءة و مدى امان عقار الميلرينون وعقارالسيلدنافيل في علاج إرتفاع ضغط الشريان الرئوي في الاطفال حديثي الولاده
Mohamed Salah Thabet ; Supervised Zahraa Mohamed Ezz Eldein , Hanan Zekry Khaled , Tamer Abdelhamed Dihome
- Cairo : Mohamed Salah Thabet , 2015
- 123 P. : facsimiles ; 25cm
Thesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Pediatrics
Background: Pulmonary hypertension in newborn (PPHN) is a critical problem facing neonatologists. Aim of the work: To determine the impact of management strategies on the outcome of PPHN. Patients and methods: Prospective descriptive study. 40 neonates with the diagnosis of PPHN who were admitted in NICUs in multi-centers from June 2014 to December 2014. Neonates divided into 2 equal groups one is treated by intravenous milrinone infusion and the other is treated by nasogastric sildenafil, it includes 33 males, 7 females; their mean gestational age was ±36.5weeks and the mean weight was 2.9 ± 0.5Kg. Results: Male neonates had higher incidence of PPHN 82.5% compared to females 17.5% .Neonates recived intravenous milrinone infusion shows statistical significant improvement than those recived nasogastric sildenafil in oxygenation index (OI)values 24 hrs after treatment(p0.010), 48 hrs later (P 0.001). Successful treatment was defined as drop of systolic pulmonary artery pressure (SPAP) below 40mmHg. There was statistical significant drop of SPAP after application ofmilrinone than sildenafil (P0.040). The mortality rate was 10/40 neonates (25%)